Avillion

16 articles with Avillion

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
• 

  Exciting Advancements in Multiple Myeloma, Asthma and Alzheimer’s

  5/16/2022

  Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.

• PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

  5/15/2022

  Full results from the positive MANDALA Phase III trial showed that PT027 at two different strengths of budesonide, an inhaled corticosteroid, used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.

• Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member

  9/5/2019

  Avillion LLP announces the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.

• Avillion Advances Co-Development Programme With Merck: IND Now Open for Phase II Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis

  2/16/2018

  Avillion is focused on this collaborative approach to advancing the development of late-stage clinical candidates for pharmaceutical company partners.

• Avillion Announces U.S. Approval of Pfizer's BOSULIF (bosutinib) for the Treatment of Patients With Newly-Diagnosed Ph+ CML

  12/20/2017

  Avillion announces that the FDA today approved a supplemental sNDA for Pfizer's BOSULIF (bosutinib).

• Avillion Appoints Kathryn J. Gregory As Chief Business Officer

  10/3/2017

• Avillion And Pfizer Release: FDA And EMA Accept Regulatory Submissions For BOSULIF® (Bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia

  8/29/2017

• Merck KGaA, Darmstadt, Germany Advances R&D Strategy Through Unique Development Model With Avillion For Anti IL-17 A/F Nanobody

  3/30/2017

• Avillion Signs Clinical Co-Development Agreement With Merck & Co. To Advance Anti IL-17 A/F Nanobody In Psoriasis

  3/30/2017

• Avillion Release: Company Strengthens Clinical And Regulatory Development Capabilities With The Appointment Of Mark Weinberg As Chief Medical Officer

  1/20/2017

• Pfizer And Avillion Announce Positive Top-Line Results For Phase III BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

  12/5/2016

• Avillion Announces Completion Of Enrolment In Phase III BFORE Trial To Assess BOSULIF (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia

  9/15/2015

• Avillion Appoints Jarrod Longcor As Chief Business Officer

  9/23/2014

• Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia

  8/11/2014

• Avillion Appoints Dr. Allison Jeynes-Ellis As Chief Executive Officer

  2/18/2014